close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (CSE:RVV)

0.0250 UNCHANGED
Streaming Delayed Price Updated: 11:07 AM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revive Therapeutics Ltd

< Previous 1 2 3 Next >
News headline image
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Via ACCESS Newswire
News headline image
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Via ACCESS Newswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Extension of Proposed Private Placement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Advances with Next-Generation Bucillamine Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Proposed Shares for Debt Transaction
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Results of Annual Shareholder Meeting
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading... 
Via Newsfile
News headline image
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.